AbbVie Inc. (FRA:4AB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 301.93B |
| Revenue (ttm) | 53.08B |
| Net Income (ttm) | 3.84B |
| Shares Out | n/a |
| EPS (ttm) | 2.16 |
| PE Ratio | 78.54 |
| Forward PE | 14.90 |
| Dividend | 5.88 (3.45%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 135 |
| Average Volume | 202 |
| Open | 169.80 |
| Previous Close | 170.40 |
| Day's Range | 166.60 - 172.20 |
| 52-Week Range | 141.80 - 203.05 |
| Beta | n/a |
| RSI | 47.61 |
| Earnings Date | Apr 25, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a cl...
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV
NEW YORK , May 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class...
Techbio Pioneer Etcembly Signs Deal With DJS Antibodies, Part of AbbVie, to Accelerate Antibody Discovery Pipeline
OXFORD, England--(BUSINESS WIRE)-- #biotech--Etcembly has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antibody therapeutics.
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
Congressional Trading Report: Rep. Jared Moskowitz Bought Over $27K In AbbVie Stock
May 9, 2025 records indicate that Representative Jared Moskowitz filed a purchase of AbbVie (NYSE: ABBV), valued between $27,027 and $405,000. According to the May filing, the transaction occurred on...
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
NEW YORK , May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV du...
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.
European pharma stocks follow Asia peers down as Trump moves to cut prices
European drugmakers stocks fell in early trading on Monday after U.S. President Donald Trump said he would sign an executive order on reducing prescription drug and pharmaceutical prices.
Recent Report Shows That Rep. Jefferson Shreve Bought Up to $4.75M Worth of Apple Stock
A May filing shows that Representative Jefferson Shreve reported a purchase in Apple (NASDAQ: AAPL), valued between $1,800,068 and $4,750,000. The transaction date is listed as May 8, 2025, with the ...
Electric vehicle surge: Tesla powers ahead while tech and healthcare struggle
Sector Overview The stock market today presents a mixed tableau of sector performances, with electric vehicles taking center stage. Tesla (TSLA) leads the charge in the auto manufacturer space with a ...
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
NEW YORK , May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class ...
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a cl...
Tesla and Google surge as healthcare sector falters in mixed market
Today's Market Overview The US stock market presents a mixed picture today, with notable performances in the consumer cyclical and communication services sectors. Giants like Tesla and Google are emer...
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join - Contact The Gross Law Firm
NEW YORK , May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV dur...
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed during a market dip. Here's the latest transactions made by the c...
Neither doctors nor pharma firm penalized for sponsored trip to Paris
Despite conclusive proof of Abbvie sponsoring foreign tours for 30 doctors, violating marketing practices, the National Medical Commission claims to lack the list of implicated doctors from the Depart...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).